#deciphera pharmaceuticals

Intra-Cellular Therapies (ITCI:NAS) Fundamental Valuation Report

Fundamental Valuation Report Intra-Cellular Therapies(ITCI:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$34.43 (USD) 04/30/2021 Weighted Valuation$26.38 (USD) Overall RatingOvervalued by 23.4% Valuation Models Comparables: $26.38 (USD) Valuation Methods This company…

Intra-Cellular Therapies (ITCI:NAS) Fundamental Valuation Report

Fundamental Valuation Report Intra-Cellular Therapies(ITCI:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$34.43 (USD) 04/30/2021 Weighted Valuation$26.38 (USD) Overall RatingOvervalued by 23.4% Valuation Models Comparables: $26.38 (USD) Valuation Methods This company…

Editas Medicine (EDIT:NAS) Fundamental Valuation Report

Fundamental Valuation Report Editas Medicine(EDIT:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$40.99 (USD) 03/24/2021 Weighted Valuation$40.70 (USD) Overall RatingFairly valued to slightly Overvalued by 0.7% Valuation Models Adjusted Book Value: $35.48 (USD) Valuation…

    Altiratinib DCC-2701; DP-5164 CAS :1345847-93-9 N-[4-({2-[(cyclopropylcarbonyl)amino]pyridin-4-yl}oxy)-2,5-difluorophenyl]-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)-2,5-difluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Mechanism of Action:MET/TIE2/VEGFR2/TRK (A,B,C) kinase inhibitor Indication:invasive solid tumors. The…